RxDoctor Payments Data

Summaya Latif, MD

Internal Medicine · Medford, ORNPI 1356737118

Payments from drug & device makers

$585in general payments, 2019–2025

Across 30 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$166
  • Novo Nordisk$100
  • Medtronic$58
  • Ascendis Pharma Endocrinology Inc$57
  • Tandem Diabetes Care, Inc.$48
  • Lilly USA, LLC$47
  • plus $109 from 5 others

What the payments were for

  • Food & beverage$56196%
  • Education$244%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$585 in reported general payments places this provider in the 85th percentile of 1,363 internal medicine providers in Oregon.

See all internal medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$81,113
Medicare patients
399
Services billed
1,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide191$247,173
JardianceEmpagliflozin90$109,573
TymlosAbaloparatide40$105,923
MounjaroTirzepatide72$92,154
TrulicityDulaglutide56$73,674
Semglee (Yfgn) PenInsulin Glargine-Yfgn66$49,769
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog33$43,581
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog60$33,654
Humalog Kwikpen U-100Insulin Lispro39$15,477
DapagliflozinDapagliflozin Propanediol13$11,076
Repatha SureclickEvolocumab11$10,610
Lantus SolostarInsulin Glargine,hum.Rec.Anlog60$10,168
Insulin Aspart FlexpenInsulin Aspart22$9,693
Novolog FlexpenInsulin Aspart22$6,665
SynthroidLevothyroxine Sodium72$6,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$100$250,720202 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$47$171,142154 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,363 internal medicine providers in Oregon.

Other internal medicine in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →